North America Allergy Immunotherapy Market Size & Outlook
North America allergy immunotherapy market, 2016-2027 (US$M)
Related Markets
North America allergy immunotherapy market highlights
- The North America allergy immunotherapy market generated a revenue of USD 308.4 million in 2019.
- The market is expected to grow at a CAGR of 10.6% from 2020 to 2027.
- In terms of segment, subcutaneous immunotherapy was the largest revenue generating treatment type in 2019.
- Sublingual immunotherapy is the most lucrative treatment type segment registering the fastest growth during the forecast period.
- Country-wise, U.S. is expected to register the highest CAGR from 2020 to 2027.
North America data book summary
| Market revenue in 2019 | USD 308.4 million |
| Market revenue in 2027 | USD 689.5 million |
| Growth rate | 10.6% (CAGR from 2019 to 2027) |
| Largest segment | Subcutaneous immunotherapy |
| Fastest growing segment | Sublingual immunotherapy |
| Historical data covered | 2016 - 2018 |
| Base year for estimation | 2019 |
| Forecast period covered | 2020 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Subcutaneous immunotherapy, Sublingual immunotherapy |
| Key market players worldwide | Merck KGaA, Allergy Therapeutics PLC, DBV Technologies SA ADR, ASIT biotech, Circassia, Mylan, DMK Pharmaceuticals Corp, Alk-Abello A/S Class B, Desentum, HAL Allergy Group, HollisterStier Allergy, Stallergenes Greer |
Other key industry trends
- In terms of revenue, North America region accounted for 19.3% of the global allergy immunotherapy market in 2019.
- Globally, Europe is projected to lead the regional market in terms of revenue in 2027.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 255.9 million by 2027.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Allergy Immunotherapy Market Scope
Allergy Immunotherapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
North America allergy immunotherapy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to allergy immunotherapy market will help companies and investors design strategic landscapes.
Subcutaneous immunotherapy was the largest segment with a revenue share of 83.98% in 2019. Horizon Databook has segmented the North America allergy immunotherapy market based on subcutaneous immunotherapy, sublingual immunotherapy covering the revenue growth of each sub-segment from 2016 to 2027.
The North America allergy immunotherapy market is expected to grow with a significant rate throughout the forecast period owing to rise in prevalence of allergic disorders and expected approval of novel products through the forecast period.
Adamis Pharmaceuticals Corporation, a U.S. based biopharmaceutical company is developing products for allergy and respiratory markets. The company plans to pursue 505 (b) (2) filings to obtain regulatory approval for its products in order to minimize time and costs.
Mylan N.V., one of the leading players of emergency allergy shots in the U.S., faced manufacturing delays in 2019 which subsequently lead to a shortage of its leading allergy product Epi Pens in North America.
Reasons to subscribe to North America allergy immunotherapy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of North America allergy immunotherapy market databook
-
Our clientele includes a mix of allergy immunotherapy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America allergy immunotherapy market, including forecasts for subscribers. This continent databook contains high-level insights into North America allergy immunotherapy market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
Partial client list
North America allergy immunotherapy market size, by country, 2016-2027 (US$M)
North America Allergy Immunotherapy Market Share, 2019 & 2027 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
